keyboard_arrow_up

Biosimilars Rheumatoid Arthritis Market Analysis and Forecast to 2023

RnRMarketResearch.com offers “Biosimilars (Rheumatoid Arthritis) – Forecast and Market Analysis to 2023”global research report on its store.

Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints . It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023. The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2013 and 2023. With the anti-TNFs as extremely effective therapies for RA, the market is extremely competitive for new entrants and will undergo further pressure as biosimilars are approved and launch.

With the cost of biologic therapies being very high, at an annual cost of at least $25,000, global healthcare systems need a reprieve from the expense. On September 9, 2013, Hospira’s Inflectra and Celltrion’s Remsima, which are both biosimilars of J&J’s Remicade, were approved by the European Commission (EC) for marketing in the EU for multiple autoimmune diseases, including RA, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, and psoriatic arthritis. Remsima and Inflectra have been rolled out in selected European markets, although their launch in the 5EU is still pending due to potential intellectual property protections in these healthcare markets. The US-based generics company, Hospira, will market Inflectra in the EU, while the South Korean biotechnology company, Celltrion, the original developer of the infliximab biosimilar, will do so as well, but under the brand name Remsima, based on a collaboration forged between the two companies in 2009.

Complete report is available at http://www.rnrmarketresearch.com/biosimilars-rheumatoid-arthritis-forecast-and-market-analysis-to-2023-market-report.html .

Scope of The Report:

  • Overview of Rheumatoid Arthritis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Biosimilars including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Biosimilars for the top 10 countries from 2013 to 2023.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan, Australia, China and India.

Reasons to Buy This Report:

  • Understand and capitalize by identifying products that are most likely to ensure a robust return.
  • Stay ahead of the competition by understanding the changing competitive landscape for Rheumatoid Arthritis.
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
  • Make more informed business decisions from insightful and in-depth analysis of Biosimilars performance.
  • Obtain sales forecast for Biosimilars from 2013-2023 in top 10 countries (the US, France, Germany, Italy, Spain, the UK and Japan, Australia, China and India).

Order a copy of this report at http://www.rnrmarketresearch.com/contacts/purchase?rname=312798 .

Table of Content for “Biosimilars (Rheumatoid Arthritis) – Forecast and Market Analysis to 2023” research report includes:

3 Disease Overview 15

3.1 Etiology and Pathophysiology 15

3.1.1 Etiology 15

3.1.2 Pathophysiology 15

3.2 Symptoms 19

3.3 Prognosis 20

3.4 Quality of Life 20

4 Disease Management 21

4.1 Diagnosis and Treatment Overview 21

4.1.1 Diagnosis 21

4.1.2 Treatment Guidelines 23

4.1.3 Leading Prescribed Drugs for the Treatment of RA 33

4.1.4 Clinical Practice 34

5 Competitive Assessment 39

5.1 Overview 39

6 Inflectra/Remsima (infliximab biosimilar) 41

6.1 Overview 41

6.2 Efficacy 42

6.3 Safety 42

6.4 SWOT Analysis 43

6.5 Forecast 43

7 Biosimilars 44

7.1 Introduction 44

7.2 Hospira's Inflectra Versus J&J's Remicade in Key Autoimmune Diseases 45

7.3 Biosimilars in the Immunology Community 46

7.4 By the Numbers: Biosimilars in Development 47

7.5 The Impact of Biosimilars Will be Felt Throughout the Pharmaceutical Industry 51

7.6 Uptake of Biosimilars for RA is Expected to Vary by Market 52

7.7 Biosimilars' Forecast 55

7.7.1 Etanercept Biosimilars 55

7.7.2 Adalimumab Biosimilars 56

7.7.3 Infliximab Biosimilars 58

7.7.4 Certolizumab Pegol Biosimilars 59

7.7.5 Abatacept Biosimilars 60

7.7.6 Tocilizumab Biosimilars 61

7.7.7 Rituximab Biosimilars 62

1.1 List of Tables

Table 1: Symptoms of RA 19

Table 2: 1987 ACR Diagnostic Criteria for RA 22

Table 3: 2010 ACR/EULAR Diagnostic Criteria for RA 23

Table 4: Treatment Guidelines for RA Used by Each Country in the 10MM 26

Table 5: ACR 2012 Criteria for RA Remission and Low/Moderate/High Disease Activity 29

Table 6: EULAR 2013 Criteria for RA Remission 30

Table 7: Most Prescribed Biologics for RA (After csDMARDs) in the Global Markets, 2014 34

Table 8: Leading Branded Treatments for RA 2014 40

Table 9: Product Profile - Inflectra/Remsima 42

Table 10: Inflectra/Remsima SWOT Analysis, 2014 43

Table 11: Biosimilars Pipeline for RA, 2013 48

Table 12: Physician Uptake of Biosimilar Products for RA Across the 10MM, 2014 54

Table 13: Global Sales Forecasts ($m) for Etanercept Biosimilars, 2013-2023 55

Table 14: Global Sales Forecasts ($m) for Adalimumab Biosimilars, 2013-2023 56

Table 15: Global Sales Forecasts ($m) for Infliximab Biosimilars, 2013-2023 58

Table 16: Global Sales Forecasts ($m) for Certolizumab Pegol Biosimilars, 2013-2023 59

Table 17: Global Sales Forecasts ($m) for Abatacept Biosimilars, 2013-2023 60

Table 18: Global Sales Forecasts ($m) for Tocilizumab Biosimilars, 2013-2023 61

Table 19: Global Sales Forecasts ($m) for Rituximab Biosimilars, 2013-2023 62

Table 20: Key Patent Expiries 72

Table 21: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 78

Priced at US $3495 for a single user PDF, a discount on this research report can be requested at http://www.rnrmarketresearch.com/contacts/discount?rname=312798 .

About Us:

RnR Market Research library offers syndicated reports by market research publishers from across the globe. We help you find the most relevant business intelligence from ready-to-buy syndicated market research studies. Not limited to industry reports covering telecommunication, healthcare, pharmaceutical, financial services, energy, technology, real estate, logistics, F&B , media and more, RnR Market Research also offers company data, country profiles, trends, information and analysis on the sector of your interest. (http://www.rnrmarketresearch.com/latest_reports).